Antiretroviral Treatment and Antihypertensive Therapy

Author(s): Nicolás R. Robles*, Francesco Fici, Julian Valladares, Guido Grassi

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 40 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

The presence of hypertension among the population with human immunodeficiency virus (HIV) has become a new threat to the health and well-being of people living with this disease, in particular, among those who received antiretroviral therapy. The estimated prevalence of high blood pressure in HIV‐infected patients is significantly higher than the rate observed in HIV‐uninfected subjects. The approach to the HIV-positive patient requires the assessment of individual cardiovascular risk and its consideration when designing the individualized target. On the other hand, the numerous pharmacological interactions of antiretroviral (ARV) drugs are essential elements to take into account. Serum levels of any kind of antihypertensive drugs may be influenced by the coadministration of protease inhibitors, non-nucleoside reverse transcriptase inhibitor, or other antiretroviral. Similarly, plasma concentrations of antiretroviral drugs can be increased by the concomitant use of calcium channel blockers or diuretics. In this regard, the treatment of high blood pressure in HIV patients should be preferentially based on ACE inhibitors or thiazide/thiazide-like diuretics or their combination.

Keywords: Antiretroviral, hypertension, antihypertensive treatment, HIV infection, interactions, cardiovascular disease.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 40
Year: 2021
Published on: 09 August, 2021
Page: [4116 - 4124]
Pages: 9
DOI: 10.2174/1381612827666210810090805
Price: $65

Article Metrics

PDF: 22